WASHINGTON (Reuters) - The U.S. House of Representatives on Saturday passed legislation that would give the Food and Drug Administration more authority to regulate companies that compound sterile drugs and ship them across state lines.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The bill, called the Drug Quality and Security Act, now goes to the Senate for a vote. House and Senate committees agreed on the legislation on Wednesday.
Introduced after a deadly outbreak of fungal meningitis killed more than 50 people last year, the act would also create a national set of standards to track pharmaceuticals through the distribution chain to help thwart the introduction of fake medication into the drug supply.
The fungal meningitis outbreak was traced to a tainted steroid sold by the New England Compounding Center in Framingham, Massachusetts.
Complaints from companies that felt previously proposed laws would cost too much to implement helped derail earlier attempts to create such national standards to track and trace drugs.
(Reporting by Gabriel Debenedetti; Editing by Doina Chiacu)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp